Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NPSP NPS Pharmaceutical -- Ignore unavailable to you. Want to Upgrade?

To: biowa who wrote (81)	3/13/2000 2:40:00 PM
From: sa-mule	Read Replies (1) \| Respond to of 363

This stock had a good chart and great volume, especially the day of the decline, before the decline of course. I noticed that the volume is anemic now though. I am really suprised this stock is down over 20% since last week on NO news. I am not going anywhere though.

To: biowa who wrote (81)	4/2/2000 11:41:00 PM
From: Spekulatius	Read Replies (1) \| Respond to of 363

NPSP's 10K NPSP 10k was posted an March 30 at edgar-online edgar-online.com The 10k gives a quite comprehensive overview over NPSP's development programs. NPSP's pipeline looks pretty solid. I got drawn to NPSP through the recent news of the ABT collaboration for NPS 1776 and bought some shares. I was wondering why they partnered this one so early after Phase I trials,until I read in a Wall Street transcript that NPS 1776 is chemically similar to Abott's Depakote, but seems to have a better side effect profile. Depakote, is Abott's 700M$ drug for bipolar disorder indication. ABT got really aggressive in 1999 partnering up with biotechs. The deals look smart to me, so I follow their footsteps in biotech land.